Brokerages Set Guardant Health, Inc. (NASDAQ:GH) PT at $40.31

Shares of Guardant Health, Inc. (NASDAQ:GH) have been given a consensus recommendation of “Moderate Buy” by the eighteen brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $40.00.

A number of equities analysts have issued reports on GH shares. Craig Hallum increased their price target on Guardant Health from $28.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. UBS Group increased their price objective on Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, August 21st. Piper Sandler increased their price objective on Guardant Health from $30.00 to $34.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. The Goldman Sachs Group increased their price objective on Guardant Health from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 17th. Finally, Sanford C. Bernstein cut their price objective on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday.

Hedge Funds Weigh In On Guardant Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ARK Investment Management LLC boosted its stake in Guardant Health by 233.5% in the 3rd quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company’s stock worth $34,701,000 after purchasing an additional 1,059,104 shares during the period. JNBA Financial Advisors acquired a new position in shares of Guardant Health during the 3rd quarter worth about $26,000. Fullcircle Wealth LLC boosted its stake in shares of Guardant Health by 105.4% during the 3rd quarter. Fullcircle Wealth LLC now owns 13,642 shares of the company’s stock worth $303,000 after buying an additional 7,000 shares during the last quarter. US Bancorp DE boosted its stake in shares of Guardant Health by 33.8% during the 3rd quarter. US Bancorp DE now owns 33,022 shares of the company’s stock worth $758,000 after buying an additional 8,346 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Guardant Health by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 23,661 shares of the company’s stock worth $543,000 after buying an additional 9,283 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Stock Up 5.1 %

Shares of NASDAQ GH opened at $23.00 on Friday. The stock has a fifty day moving average price of $23.15 and a two-hundred day moving average price of $25.65. The company has a quick ratio of 6.07, a current ratio of 6.40 and a debt-to-equity ratio of 16.70. Guardant Health has a 1 year low of $15.81 and a 1 year high of $37.04.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). The firm had revenue of $177.24 million for the quarter, compared to the consensus estimate of $162.59 million. Guardant Health had a negative net margin of 76.23% and a negative return on equity of 418.21%. The business’s revenue for the quarter was up 29.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.67) earnings per share. As a group, equities analysts forecast that Guardant Health will post -3.31 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.